DexCom Inc (XTER:DC4)
€ 78.11 5.59 (7.71%) Market Cap: 29.79 Bil Enterprise Value: 29.88 Bil PE Ratio: 47.63 PB Ratio: 15.70 GF Score: 73/100

DexCom Inc at Canaccord Genuity Growth Conference Transcript

Aug 07, 2019 / 06:00PM GMT
Release Date Price: €2.91
Kyle William Rose
Canaccord Genuity Corp., Research Division - Senior Analyst

Great. So we're going to continue on with the MedTech team here. I want to thank everybody for joining us again. This is 39th installment of Canaccord's Global Growth Conference. I appreciate everyone's participation.

I'm Kyle Rose. I'm one of the MedTech analysts here at Canaccord. I covered the diabetes space. We're very excited to have with us DexCom this afternoon. DexCom is a leader in the glucose-monitoring segment of the diabetes space with what we view as really the best-in-class technology. So very excited to have with us Steve Pacelli, the Executive Vice President of Strategy and Corporate Development as well as Quentin Blackford, the CFO.

There's a lot going on in diabetes. And I think it's a very compelling space. Valuations are -- if there's not a lot of volatility, valuation are stretched. But when I take a step back and I look at the underlying fundaments of the market, and they've never been stronger, both patient additions and then also your underlying technology. So I think there's a lot

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot